|
A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. Clinical Trials Information presented on Clinical Trials Search is not intended to be a substitute for qualified health advice, trips or treatment by using a genuine doctor. We aren't doctors. Always consult your mD on A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. conditions. Clinical Trials Search.org is a site committed to listing clinical research studies in human subjects. A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. Clinical research trials and A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. health trials take place in a lot of of cities across the US. A clinical trial or clinical study is a research project with human volunteer subjects. Clinical drug trials and pharmaceutical clinical trials generally measure the potency of new drugs. The aim of the studies / projects is to answer specific human medical questions. Clinical trials are a popular manner for physicians, government agencies, and private sector corporations to discover remedies for all kinds of circumstances, like A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.. A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. Clinical Trials and other clinical trials allow for volunteers to have health treatment alternatives before they are available to the general public. Many times the test subjects obtain treatment for without cost, and occasionally they are paid for their time. Sometimes there is a cost for a A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. clinical trial. Subjects oftentimes recieve the most effective healthcare possible for their A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. condition. Hazards are a reality, however, and could include additional or frequent doctor visits, healthcare dangers (perhaps life-threatening), and/or the treatment being ineffective. Trials are federally governed with exacting guidelines to protect clinical trials subjects.
|
|
|
|
|
|
|
Home > "A" Clinical Trials Conditions > A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body. A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.
A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.
For Condition: Prostate Cancer
Status: Recruiting
Sponsor(s): Abgenix , Immunex Corporation
Synopsis: A clinical trial examining the safety and effectiveness of ABX-EGF when given to patients with prostate cancer with or without tumor in other parts of the body. Patients will be treated for a maximum of 48 doses (6 treatment courses; 8 doses per course) or until evidence of progressive disease.
Details:
Eligibility:
Study Type: Interventional, Treatment, Non-Randomized, Open Label, Uncontrolled, Single Group Assignment, Safety/Efficacy Study
Minimum Age/Maximum Age: 18 Years/
Genders: Male
Protocol Entry Criteria: Inclusion Criteria: - Male 18 years of age or older - Has tumor tissue available for diagnostics - Failed front line luteinizing hormone-releasing hormone analogue (LHRH) such as leuprolide or goserelin, or failed orchiectomy, as evidenced by disease progression. Patients must continue on a LHRH analogue (unless the patient had an orchiectomy) throughout the course of the study - ECOG score of 0 or 1 Exclusion Criteria: - Any prior chemotherapy for prostate cancer besides hormonal therapy (including no prior EGFr targeting agent) - Prior history of cancer other than prostate carcinoma within the past 5 years that has required treatment or been active (prior basal cell carcinoma is allowed) - Known to be HIV positive - Myocardial infarction within one year prior to entering the study
Total Enrollment: 50
Location and Contact Information:
University of Pittsburgh Cancer Institute, Hillman Cancer Center *Recruiting*
Pittsburgh, Pennsylvania, 15232
United States
Recruiting Janie Hofacker 412-647-8252
Fox Chase Cancer Center *Recruiting*
Philadelphia, Pennsylvania, 19111
United States
Recruiting Central Referral 888-369-2427
Urology San Antonio Research *Recruiting*
San Antonio, Texas, 78229
United States
Recruiting Beatrice Escamilla 210-617-4116
Advanced Research Institute *Recruiting*
New Port Richey, Florida, 34652
United States
Recruiting Kristin White 727-842-9561
Stanford Medical Center *Recruiting*
Stanford, California, 94303
United States
Recruiting Sandy Srinivas 650-725-2078
University of Washington *Recruiting*
Seattle, Washington, 98109
United States
Recruiting Karlee Olson 206-288-1349
UCLA School of Medicine *Recruiting*
Los Angeles, California, 90095
United States
Recruiting Nazy Zomorodian 310-794-7704
Madigan Army Medical Center *Recruiting*
Tacoma, Washington, 98431
United States
Recruiting Shari Aynes 253-968-3710
University of Alabama at Birmingham *Recruiting*
Birmingham, Alabama, 35294
United States
Recruiting Andres Forero 205-934-7167
Additional Information:
Study ID Numbers: ABX-0310; ABX-EGF
Study Start Date: April 2003
Record last reviewed: June 2003
Additional information available at: clinicaltrials.gov
Clinicaltrials.gov Reference link: NCT00061126
Other Prostate Cancer Studies:
1. ProvengeĀ® Immunotherapy Vaccine for the Treatment of Metastatic Prostate Cancer after Failing Hormone Therapy
2. Phase I Study of Weekly Intravenous PS-341 Plus Mitoxantrone
3. Clinical Trial for Prostate Cancer
4. EF5 Prior to Surgery or Biopsy in Patients With Breast, Prostate, or Cervical Cancer or High Grade Soft Tissue Sarcoma
5. Treatment With an Investigational Compound for the Prevention of Prostate Cancer
Related Studies:
Other Prostate Cancer Clinical Trials
Other California Clinical Trials
Other Los Angeles Clinical Trials
A clinical trial evaluating ABX-EGF (a monoclonal antibody) given to patients with prostate cancer with or without tumor in other parts of the body.
|
|
|
|
|
|
|
|